Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases

Moderna

Moderna

MRNA

0.00
  • Moderna outlined new early-stage pipeline moves at its Science Day event, with no new trial results disclosed in the update.
  • A Phase 1/2 study of mRNA-2808 in multiple myeloma is ongoing, with early signals described as encouraging for the T-cell engager approach.
  • The company is moving mRNA-2151, a second multiplexed T-cell engager program, toward early development in ovarian cancer, supported by the mRNA-2808 signal.
  • mRNA-6007, an in vivo CAR-T program for autoimmune disease, entered early development with an initial clinical focus on systemic lupus erythematosus.
  • Moderna expects additional readouts later in 2026, including Phase 1 part B data for mRNA-1195 in EBV-associated conditions such as multiple sclerosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.